ClinicalTrials.gg
Drug

Tovorafenib clinical trials

Also written TAK-580 and DAY101.

studies test it
14
open now
6
in phase 3
1
first study started
2011

How each study uses tovorafenib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the tovorafenib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
23 Apr 2024 · OJEMDA · NDA 217700 (FDA, Drugs@FDA)
European Union
20 Apr 2026 · Ojemda · EMEA/H/C/006140 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Tovorafenib
10

Brand

Ojemda®
1

Development codes

TAK-580
5
DAY101
4
MLN2480
4
AMG-2112819
1
BSK1369
1

Studies by the year they started

13 studies that test it; most in 2021 (2); 1 more planned to start later

Studies that test tovorafenib, by start year
YearStudies
20111
20151
20161
20181
20212
20222
20231
20242
20262

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
7
Phase 2
6
Phase 3
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 8 · Other 6

Day One Biopharmaceuticals, Inc. (4) · Millennium Pharmaceuticals, Inc. (3) · National Cancer Institute (NCI) (2) · Ipsen (1) · Karen D. Wright, MD (1) · Nationwide Children's Hospital (1) · Sabine Mueller, MD, PhD (1) · Daniel Morgenstern (1)

Often tested with

Tested in the same studies.

Vinblastine (1) · Pimasertib (1) · Plozalizumab (1) · Vedolizumab (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 4, 1 in phase 3

Studies that test tovorafenib, phase 3 first.

Studies

Open first, then newest update. How each study uses tovorafenib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 14

Codes

What other systems call tovorafenib · ClinicalTrials.gg INT000905

  • MeSH (NLM) C000626518tovorafenibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) ZN90E4027MTOVORAFENIBConfirmed FDA, NLM
  • NCI Thesaurus C106254TovorafenibOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.